HealthGrades Recognized Doctors are board certified in the specialty they practice; have never had their license restricted or
revoked; are free of state or federal disciplinary actions; and are free of any malpractice claims.
Professional Interests:
Breast Cancer
Patient / Medical Philosophy
Tari King, M.D. is an Assistant Attending Surgeon on the Breast Service in the Department of Surgery at MSKCC. Her clinical expertise is in the diagnosis and surgical treatment of breast cancer. In addition to her clinical practice, Dr. King has an active interest in translational research and is the PI of the William F. Keck Laboratory for Breast Cancer Research at Memorial Sloan-Kettering Cancer Center.
The overriding theme of the translational research performed in my laboratory has been to elucidate the molecular genetics of breast cancer, focusing on high risk populations such as those with hereditary breast cancer and high risk benign lesions, as well as on the mechanisms involved in the progression from non-invasive to invasive disease.
One of our major efforts has to been to elucidate the molecular genetics underpinning the progression of lobular carcinoma in situ (LCIS) to invasive disease. Historical data suggests that LCIS is not an obligate precursor to invasive disease; however recent clinical and laboratory observations have re-opened the debate regarding the true significance of LCIS and its possible malignant potential. Our hypothesis is that LCIS is a heterogeneous lesion which can be characterized at the molecular level, and that molecular alterations present in LCIS can be used to predict the risk of subsequent ILC. We are currently testing this hypothesis using a variety of gene expression assays with the support of the genomics core facility. This project is supported by an Exceptional Project Award from the Breast Cancer Alliance and by the 2009 Association of Women Surgeons Foundation Award.
In addition to this work we are investigating the signaling pathways involved in the progression of ductal carcinoma in situ to invasive ductal cancer. Specifically we are focusing on the role of Her2-neu and other downstream targets in the Her2/PI3K pathway. In collaboration with Dr. Neal Rosen and members of his laboratory, we are utilizing immunohistochemistry with novel antibodies to investigate these pathways in parallel to pre-clinical assays being performed by Dr. Rosen’s team. We are also working with Dr. Rosen’s team to investigate potential mechanisms of Herceptin resistance among patients who have progressed on anti-Her 2 therapy.
Experience / Training
Specialty:
General Surgery
(HealthGrades has verified that Dr. Tari A. King, MD is board certified by the American Board of Surgery)
University of Colorado Health Sciences Center Denver, CO
Residency:
Ochsner Medical Institutions New Orleans, LA
Fellowship:
Memorial Sloan-Kettering Cancer Center
Health Plan / Other
Health Plans:
United Health Care
Disciplinary Actions
HealthGrades has examined disciplinary actions within the last five years from the Office of Inspector General and 50 state medical boards.
HealthGrades could not detect any disciplinary actions for Dr. Tari A. King, MD
as of 11/26/2009. Note: HealthGrades reports on state and federal disciplinary actions (if any) from the previous five years.
Malpractice History
HealthGrades did not find any closed malpractice claims for
Dr. Tari A.
King, MD
in the states of California, Connecticut, Florida, Georgia, Idaho, Indiana, Massachusetts, Maryland, North Dakota, New Jersey, New York, Oregon, Tennessee, Texas, Virginia, Vermont, or West Virginia.
Learn More
Note: HealthGrades obtains physician information from a variety of sources. Some information that is not designated as HealthGrades verified has been reported by the physician.